Novo Nordisk, known for making drugs for diabetes and obesity, is strengthening its focus on consumers. This is evidenced by the appointment of Poul Weihrauch, CEO of Mars, as an observer of the board. This move indicates Novo Nordisk's effort to better understand the consumer market and adapt to its needs. The FDA (US Food and Drug Administration) has approved a new gene therapy.